LivaNova: RECOVER depression trial enrollment extended to 475 unipolar patients

LivaNova PLC

Independent Statistical Analysis Committee advises to continue enrollment from 450 to 475 unipolar patients.
Trial uses interim analyses every 25 patients; predictive probability of success not yet reached.
Successful trial could support reconsideration of CMS reimbursement for VNS Therapy for difficult-to-treat depression.
After last RCT patient completes 12-month follow-up, final analysis will be conducted on complete dataset.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.